<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113810</url>
  </required_header>
  <id_info>
    <org_study_id>1093-2021</org_study_id>
    <nct_id>NCT05113810</nct_id>
  </id_info>
  <brief_title>The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19</brief_title>
  <official_title>A Pilot, Randomized, Open-label Trial to Determine the Feasibility, Safety, Efficacy, and Pharmacokinetics of Nebulized HCQ01for the Treatment of Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACDIMA Biocenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amman Pharmaceutical Industries</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sana Pharmaceutical Industry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, randomized, single-center, parallel group, open-label controlled study to&#xD;
      evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus&#xD;
      Standard of Care (SOC) versus SOC alone in hospitalized COVID-19 patients. The Jordanian&#xD;
      Ministry of Health (MOH) is the study sponsor, and the study will be conducted at MOH&#xD;
      COVID-19 hospitals.&#xD;
&#xD;
      Approximately 110 patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be&#xD;
      enrolled and randomized 1:1 to the treatment and control arms where they will receive ten&#xD;
      doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm&#xD;
      where treatment will follow the MOH SOC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 4, 2021</start_date>
  <completion_date type="Anticipated">May 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who improve by at least one level lower on the 11-point World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI), where patients are scored on a scale of 0-10 with 0 being uninfected and 10 being dead</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Indicator: Recruitment (Proportion of participants enrolled in the study)</measure>
    <time_frame>Screening / Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Indicator: Recruitment retention (Proportion of consented participants that complete the study</measure>
    <time_frame>Up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Indicator: related to IMP and deviations (Feasibility endpoints include protocol deviations in terms of timing and delivery of scheduled medication)</measure>
    <time_frame>Day 6</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>2019 Novel Coronavirus</condition>
  <arm_group>
    <arm_group_label>First Arm (Hydroxychloroquine sulfate, 5 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Arm (Continued Standard of Care (SOC) Therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive continued standard of care therapy for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCQ01</intervention_name>
    <description>HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization</description>
    <arm_group_label>First Arm (Hydroxychloroquine sulfate, 5 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care (SOC) for COVID-19</intervention_name>
    <description>Standard of care (SOC) for COVID-19</description>
    <arm_group_label>Second Arm (Continued Standard of Care (SOC) Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at&#xD;
             screening.&#xD;
&#xD;
          2. Patients with a history of retinopathy, sickle cell disease or trait, psoriasis,&#xD;
             porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder,&#xD;
             known active tuberculosis or history of incompletely treated tuberculosis, patients on&#xD;
             chronic immunosuppression for other medical conditions such as rheumatological&#xD;
             disorders, inflammatory bowel disease, or in patients with organ transplants.&#xD;
&#xD;
          3. Patients admitted in ICU.&#xD;
&#xD;
          4. Taking medications which may lead to interactions with hydroxychloroquine, including&#xD;
             penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone ,&#xD;
             cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and&#xD;
             during the duration of the study.&#xD;
&#xD;
          5. History of Glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          6. Pre-treatment corrected QT interval (QTc) ≥450 milliseconds.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at&#xD;
             screening.&#xD;
&#xD;
          2. Patients with a history of retinopathy, sickle cell disease or trait, psoriasis,&#xD;
             porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder,&#xD;
             known active tuberculosis or history of incompletely treated tuberculosis, patients on&#xD;
             chronic immunosuppression for other medical conditions such as rheumatological&#xD;
             disorders, inflammatory bowel disease, or in patients with organ transplants.&#xD;
&#xD;
          3. Patients admitted in ICU.&#xD;
&#xD;
          4. Taking medications which may lead to interactions with hydroxychloroquine, including&#xD;
             penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone ,&#xD;
             cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and&#xD;
             during the duration of the study.&#xD;
&#xD;
          5. History of Glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          6. Pre-treatment corrected QT interval (QTc) ≥450 milliseconds.&#xD;
&#xD;
          7. Acute or chronic kidney disease (stage-4 or -5 renal impairment; eGFR&lt;30 mL/min/1.73&#xD;
             m2 or hemodialysis).&#xD;
&#xD;
          8. Liver Child-Pugh grade C.&#xD;
&#xD;
          9. Patients with Hypokalemia (&lt;3.5mmol/L), Hypocalcemia (&lt;2.2mmol/L), Hypomagnesemia&#xD;
             (&lt;0.66mmol/L). Will be included after correction.&#xD;
&#xD;
         10. Need for mechanical ventilation.&#xD;
&#xD;
         11. History of hypersensitivity to hydroxychloroquine.&#xD;
&#xD;
         12. History of Chronic Hepatitis B or hepatitis C infections.&#xD;
&#xD;
         13. History of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         14. Concurrent serious illness including, but not limited to, any of the following:&#xD;
&#xD;
               -  Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,&#xD;
                  myocardial infarction, or unstable angina).&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure.&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication. -Peripheral vascular disease ≥&#xD;
                  grade 2 within the past year. -&#xD;
&#xD;
               -  Psychiatric illness/social situation that would limit compliance with study&#xD;
                  requirements. -COPD, Lung cancer, and moderate to severe asthma.&#xD;
&#xD;
         15. Any other significant finding based on the judgment of the PI would increase the risk&#xD;
             of having an adverse outcome from participating in this study.&#xD;
&#xD;
         16. Any other concomitant treatment based on the judgment of the PI would increase the&#xD;
             risk of having an adverse outcome from participating in this study.&#xD;
&#xD;
         17. Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 80 days of signing the informed&#xD;
             consent/assent for this current trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feras Hawari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Jordanian Ministry of Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmeen Dodin, MSc</last_name>
    <phone>00962798950958</phone>
    <email>YD.14502@KHCC.JO</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laith Alawneh, MD</last_name>
    <phone>0795098009</phone>
    <email>layth.m.alawneh@gmail.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Inhaled/nebulized Hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

